NL8800412A - Piperazinecarbonzuurderivaat, bereiding ervan en farmaceutische preparaten die het bevatten. - Google Patents

Piperazinecarbonzuurderivaat, bereiding ervan en farmaceutische preparaten die het bevatten. Download PDF

Info

Publication number: NL8800412A
Authority: NL; Netherlands
Prior art keywords: compound; formula; salt; pharmaceutically acceptable; treatment
Prior art date: 1987-02-18

Application number

NL8800412A

Other languages

English (en)

Dutch (nl)

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-02-18

Filing date

1988-02-18

Publication date

1988-09-16

1988-02-18 Application filed by Sandoz Ag filed Critical Sandoz Ag

1988-09-16 Publication of NL8800412A publication Critical patent/NL8800412A/nl

Links

238000002360 preparation method Methods 0.000 title claims description 7
239000000825 pharmaceutical preparation Substances 0.000 title description 4
KYOIKBBVCRTMEG-UHFFFAOYSA-N carbonic acid;piperazine Chemical class OC(O)=O.C1CNCCN1 KYOIKBBVCRTMEG-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 89
238000011282 treatment Methods 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
208000035475 disorder Diseases 0.000 claims description 16
150000004682 monohydrates Chemical class 0.000 claims description 15
230000028327 secretion Effects 0.000 claims description 12
238000000034 method Methods 0.000 claims description 10
210000003169 central nervous system Anatomy 0.000 claims description 9
208000019901 Anxiety disease Diseases 0.000 claims description 7
206010020852 Hypertonia Diseases 0.000 claims description 7
208000002193 Pain Diseases 0.000 claims description 7
208000009205 Tinnitus Diseases 0.000 claims description 7
230000036506 anxiety Effects 0.000 claims description 7
206010015037 epilepsy Diseases 0.000 claims description 7
201000000980 schizophrenia Diseases 0.000 claims description 7
231100000886 tinnitus Toxicity 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
230000003412 degenerative effect Effects 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 5
201000006474 Brain Ischemia Diseases 0.000 claims description 4
206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
125000003710 aryl alkyl group Chemical group 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
206010008118 cerebral infarction Diseases 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
208000028867 ischemia Diseases 0.000 claims description 2
NLHLPHWVRWZJMN-UHFFFAOYSA-N 1-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CNCCN1CC=CP(O)(O)=O NLHLPHWVRWZJMN-UHFFFAOYSA-N 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
102000009151 Luteinizing Hormone Human genes 0.000 description 14
108010073521 Luteinizing Hormone Proteins 0.000 description 14
229940040129 luteinizing hormone Drugs 0.000 description 14
238000007912 intraperitoneal administration Methods 0.000 description 13
230000000694 effects Effects 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
239000000243 solution Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
238000012360 testing method Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
-1 4-substituted 2-piperazine carboxylic acids Chemical class 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229960003604 testosterone Drugs 0.000 description 5
206010010904 Convulsion Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
230000036461 convulsion Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
210000003141 lower extremity Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000016087 ovulation Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
230000001773 anti-convulsant effect Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000006260 foam Substances 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000035939 shock Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
229960003965 antiepileptics Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000020335 dealkylation Effects 0.000 description 2
238000006900 dealkylation reaction Methods 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000007574 infarction Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
239000003158 myorelaxant agent Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000011514 reflex Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
238000006884 silylation reaction Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000012439 solid excipient Substances 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
OMZRNAXQJKWLAQ-GOSISDBHSA-N (2r)-1,4-dibenzylpiperazin-1-ium-2-carboxylate Chemical compound C([C@@H](N(CC1)CC=2C=CC=CC=2)C(=O)O)N1CC1=CC=CC=C1 OMZRNAXQJKWLAQ-GOSISDBHSA-N 0.000 description 1
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
JSSXHAMIXJGYCS-SCSAIBSYSA-N (R)-piperazine-2-carboxylic acid Chemical compound [O-]C(=O)[C@H]1CNCC[NH2+]1 JSSXHAMIXJGYCS-SCSAIBSYSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
VUBQHWMSZZVKHB-UHFFFAOYSA-N 3-bromoprop-1-en-2-ylphosphonic acid Chemical compound BrCC(=C)P(O)(O)=O VUBQHWMSZZVKHB-UHFFFAOYSA-N 0.000 description 1
VZXMZMJSGLFKQI-UHFFFAOYSA-N 4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CC=CP(O)(O)=O)CCN1 VZXMZMJSGLFKQI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
108091002531 OF-1 protein Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000029033 Spinal Cord disease Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000906446 Theraps Species 0.000 description 1
206010043994 Tonic convulsion Diseases 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000000538 analytical sample Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000002999 depolarising effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000005611 electricity Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000012173 estrus Effects 0.000 description 1
KKXWTUYDLQVOOO-UHFFFAOYSA-N ethyl 1,4-dibenzylpiperazine-2-carboxylate Chemical compound C1CN(CC=2C=CC=CC=2)C(C(=O)OCC)CN1CC1=CC=CC=C1 KKXWTUYDLQVOOO-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
229960004873 levomenthol Drugs 0.000 description 1
210000002332 leydig cell Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000003961 neuronal insult Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
230000007180 physiological regulation Effects 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
201000004240 prostatic hypertrophy Diseases 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
210000000273 spinal nerve root Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229940032330 sulfuric acid Drugs 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000012982 x-ray structure analysis Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8800412A 1987-02-18 1988-02-18 Piperazinecarbonzuurderivaat, bereiding ervan en farmaceutische preparaten die het bevatten. NL8800412A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878703749A GB8703749D0 (en)	1987-02-18	1987-02-18	Piperazinecarboxylic acid
GB8703749		1987-02-18

Publications (1)

Publication Number	Publication Date
NL8800412A true NL8800412A (nl)	1988-09-16

Family

ID=10612501

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8800412A NL8800412A (nl)	1987-02-18	1988-02-18	Piperazinecarbonzuurderivaat, bereiding ervan en farmaceutische preparaten die het bevatten.

Country Status (28)

Country	Link
JP (1)	JPH0723387B2 (xx)
KR (1)	KR960015190B1 (xx)
AT (1)	AT391320B (xx)
AU (1)	AU613009B2 (xx)
BE (1)	BE1002427A3 (xx)
CA (1)	CA1327799C (xx)
CH (1)	CH675125A5 (xx)
CY (1)	CY1739A (xx)
DE (1)	DE3804936C2 (xx)
DK (1)	DK168441B1 (xx)
ES (2)	ES2011319A6 (xx)
FI (1)	FI86733C (xx)
FR (1)	FR2610932B1 (xx)
GB (2)	GB8703749D0 (xx)
GR (1)	GR1002471B (xx)
HK (1)	HK142093A (xx)
HU (2)	HU199858B (xx)
IE (1)	IE59098B1 (xx)
IL (1)	IL85436A0 (xx)
IT (1)	IT1219447B (xx)
LU (1)	LU87129A1 (xx)
MY (1)	MY103206A (xx)
NL (1)	NL8800412A (xx)
NZ (1)	NZ223529A (xx)
PH (1)	PH25512A (xx)
PT (1)	PT86776B (xx)
SE (1)	SE467256B (xx)
ZA (1)	ZA881146B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU202111B (en) *	1988-03-11	1991-02-28	Sandoz Ag	Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component
US5086072A (en) *	1990-06-18	1992-02-04	The United States Of America As Represented By The Department Of Health And Human Services	Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
EP0488959A3 (en) *	1990-11-28	1992-08-05	Sandoz Ltd.	New uses of competitive nmda receptor antagonists
US5260286A (en) *	1992-10-16	1993-11-09	Japan Tobacco, Inc.	2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
AU5693996A (en) *	1995-05-08	1996-11-29	Lonza A.G.	Biotechnical production process of piperazine r-alpha-carbox ylic acids and piperazine s-alpha-carboxylic acid amide
ES2206928T3 (es)	1997-05-12	2004-05-16	Ortho-Mcneil Pharmaceutical, Inc.	Piperacinas sustituidas con arilo utiles en el tratamiento de la hiperplasia benigna de prostata.
GB9821179D0 (en) *	1998-09-30	1998-11-25	Merck Sharp & Dohme	Therapeutic use
JP2008124531A (ja)	2006-11-08	2008-05-29	Nec Electronics Corp	半導体装置およびオーディオプロセッサチップ
EP3427729A1 (en)	2017-07-13	2019-01-16	Paris Sciences et Lettres - Quartier Latin	Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1248531A (en) *	1984-04-17	1989-01-10	Jeffrey C. Watkins	4-substituted piperazine-2-carboxylic acids

1987
- 1987-02-18 GB GB878703749A patent/GB8703749D0/en active Pending
1988
- 1988-02-11 LU LU87129A patent/LU87129A1/fr unknown
- 1988-02-12 FR FR888801782A patent/FR2610932B1/fr not_active Expired - Lifetime
- 1988-02-12 BE BE8800177A patent/BE1002427A3/fr active
- 1988-02-12 IT IT47631/88A patent/IT1219447B/it active
- 1988-02-15 MY MYPI88000155A patent/MY103206A/en unknown
- 1988-02-15 GB GB8803438A patent/GB2201676B/en not_active Expired - Lifetime
- 1988-02-16 NZ NZ223529A patent/NZ223529A/xx unknown
- 1988-02-16 DK DK079688A patent/DK168441B1/da not_active IP Right Cessation
- 1988-02-16 HU HU88746A patent/HU199858B/hu not_active IP Right Cessation
- 1988-02-16 PH PH36514A patent/PH25512A/en unknown
- 1988-02-16 CH CH549/88A patent/CH675125A5/de not_active IP Right Cessation
- 1988-02-16 CA CA000559170A patent/CA1327799C/en not_active Expired - Fee Related
- 1988-02-16 IE IE41388A patent/IE59098B1/en not_active IP Right Cessation
- 1988-02-16 AU AU11758/88A patent/AU613009B2/en not_active Ceased
- 1988-02-16 GR GR880100084A patent/GR1002471B/el not_active IP Right Cessation
- 1988-02-16 IL IL85436A patent/IL85436A0/xx not_active IP Right Cessation
- 1988-02-17 JP JP63036458A patent/JPH0723387B2/ja not_active Expired - Lifetime
- 1988-02-17 FI FI880744A patent/FI86733C/fi not_active IP Right Cessation
- 1988-02-17 DE DE3804936A patent/DE3804936C2/de not_active Expired - Fee Related
- 1988-02-17 KR KR1019880001680A patent/KR960015190B1/ko not_active IP Right Cessation
- 1988-02-17 SE SE8800541A patent/SE467256B/sv not_active IP Right Cessation
- 1988-02-17 PT PT86776A patent/PT86776B/pt not_active IP Right Cessation
- 1988-02-17 AT AT0036788A patent/AT391320B/de not_active IP Right Cessation
- 1988-02-18 ZA ZA881146A patent/ZA881146B/xx unknown
- 1988-02-18 NL NL8800412A patent/NL8800412A/nl not_active Application Discontinuation
- 1988-02-18 ES ES888800466A patent/ES2011319A6/es not_active Expired - Lifetime
1989
- 1989-10-16 ES ES8903482A patent/ES2021904A6/es not_active Expired - Lifetime
1993
- 1993-12-30 HK HK1420/93A patent/HK142093A/xx not_active IP Right Cessation
1995
- 1995-06-09 HU HU95P/P00176P patent/HU211269A9/hu unknown
- 1995-10-20 CY CY173995A patent/CY1739A/xx unknown

Also Published As

Publication number	Publication date
ES2021904A6 (es)	1991-11-16
IE59098B1 (en)	1994-01-12
HK142093A (en)	1994-01-07
KR960015190B1 (ko)	1996-11-01
PH25512A (en)	1991-07-24
MY103206A (en)	1993-05-29
IT8847631A0 (it)	1988-02-12
AU613009B2 (en)	1991-07-25
FI880744A0 (fi)	1988-02-17
ATA36788A (de)	1990-03-15
CA1327799C (en)	1994-03-15
NZ223529A (en)	1991-02-26
ZA881146B (en)	1989-10-25
ES2011319A6 (es)	1990-01-01
FR2610932A1 (fr)	1988-08-19
DE3804936C2 (de)	1997-02-13
HUT49361A (en)	1989-09-28
GB8803438D0 (en)	1988-03-16
IL85436A0 (en)	1988-07-31
DK79688D0 (da)	1988-02-16
DE3804936A1 (de)	1988-09-01
HU199858B (en)	1990-03-28
CH675125A5 (xx)	1990-08-31
DK79688A (da)	1988-08-19
IE880413L (en)	1988-08-18
PT86776B (pt)	1992-05-29
JPH0723387B2 (ja)	1995-03-15
GR880100084A (el)	1988-12-16
FI86733B (fi)	1992-06-30
GB2201676B (en)	1991-01-02
GB8703749D0 (en)	1987-03-25
KR880009944A (ko)	1988-10-06
IL85436A (xx)	1992-12-01
IT1219447B (it)	1990-05-18
BE1002427A3 (fr)	1991-02-05
DK168441B1 (da)	1994-03-28
LU87129A1 (fr)	1988-09-20
FI880744A (fi)	1988-08-19
AT391320B (de)	1990-09-25
GB2201676A (en)	1988-09-07
SE8800541D0 (sv)	1988-02-17
CY1739A (en)	1995-10-20
FR2610932B1 (fr)	1990-11-16
PT86776A (pt)	1988-03-01
HU211269A9 (en)	1995-11-28
FI86733C (fi)	1992-10-12
GR1002471B (el)	1996-11-15
SE467256B (sv)	1992-06-22
AU1175888A (en)	1988-08-25
JPS63203691A (ja)	1988-08-23

Publication	Publication Date	Title
JPH0641475B2 (ja)	1994-06-01	置換アルファアミノ酸、その製法および医薬
US20040229866A1 (en)	2004-11-18	Method of lowering body temperature with (S)-2,3-benzodiazepines
JP2023182589A (ja)	2023-12-26	フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
JPH05508648A (ja)	1993-12-02	神経筋遮断剤
NL8800412A (nl)	1988-09-16	Piperazinecarbonzuurderivaat, bereiding ervan en farmaceutische preparaten die het bevatten.
JP2010024243A (ja)	2010-02-04	緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体
CA1054521A (en)	1979-05-15	Biological materials
KR900003301B1 (ko)	1990-05-14	2-피페라지닐-4-페닐 퀴나졸린 유도체 및 그의 산염의 제조 방법
EP0381508B1 (en)	1993-06-30	Use of cinnamamide for relaxing muscle tone
WO1999056550A1 (en)	1999-11-11	Method for treating migraine in mammals
EP0171912B1 (en)	1990-05-02	Pyrrolizidine compounds, methods for their production, and their uses
EP0573548B1 (en)	1995-07-12	Neuroprotectant agents
US4904670A (en)	1990-02-27	Pyridine derivatives having anxiety state or sleep thereapeutic properties
JP3681770B2 (ja)	2005-08-10	老年性痴呆症又はアルツハイマー病治療剤
CN108069833B (zh)	2020-11-06	苯并四环衍生物及其制备方法和在医药上的应用
HUT73438A (en)	1996-07-29	Quinoxalin-2,3-dione derivatives pericondensed with heterocycle
WO2012136356A1 (en)	2012-10-11	6,7-diydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical compositions containing the same as hypnotic or anesthetic agent and method for their preparation
JP3571114B2 (ja)	2004-09-29	麻薬拮抗剤
RU2173146C2 (ru)	2001-09-10	Производные полициклических алкалоидов как антагонисты nmda-рецептора
CZ286092B6 (cs)	2000-01-12	Pyrrolo /2,3-b/indolketony a jejich analogy, způsob jejich přípravy a jejich použití jako léčiva
JPH0352888A (ja)	1991-03-07	新規化合物、その製法及びそれを含む医薬組成物
CH635335A5 (en)	1983-03-31	2,3-Diphenylchromone derivatives, process for their preparation and their therapeutic application
JPS6118553B2 (xx)	1986-05-13

Legal Events

Date	Code	Title	Description
1995-03-01	BA	A request for search or an international-type search has been filed
1995-05-01	BB	A search report has been drawn up
1996-06-03	BC	A request for examination has been filed
1997-11-03	CNR	Transfer of rights (patent application after its laying open for public inspection)	Free format text: NOVARTIS AG
2002-10-01	BV	The patent application has lapsed